BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27218431)

  • 1. Focal fluorine-18 fluorodeoxyglucose-avid parotid findings in patients with lung cancer: prevalence and characteristics.
    Davidson T; Komissar O; Goshen E; Shalmon B; Chikman B; Ben-Nun A; Ben-Haim S
    Nucl Med Commun; 2016 Sep; 37(9):969-74. PubMed ID: 27218431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management.
    Basu S; Houseni M; Alavi A
    Nucl Med Commun; 2008 Apr; 29(4):367-73. PubMed ID: 18317302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidental focal FDG uptake in the parotid glands on PET/CT in patients with head and neck malignancy.
    Seo YL; Yoon DY; Baek S; Lim KJ; Yun EJ; Cho YK; Bae WJ; Chung EJ; Kwon KH
    Eur Radiol; 2015 Jan; 25(1):171-7. PubMed ID: 25182627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of pathologic outcome of focal FDG uptake in the parotid gland identified on whole-body FDG PET imaging.
    Mabray MC; Behr SC; Naeger DM; Flavell RR; Glastonbury CM
    Clin Imaging; 2015; 39(6):1073-9. PubMed ID: 26324219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of parotid gland incidentalomas on (18)F-FDG PET/CT.
    Makis W; Ciarallo A; Gotra A
    Clin Imaging; 2015; 39(4):667-71. PubMed ID: 25888252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis.
    Treglia G; Bertagna F; Sadeghi R; Muoio B; Giovanella L
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3617-26. PubMed ID: 25262193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Significance of Incidental Parotid Uptake in a PET/CT Study: A Diagnostic Algorithm.
    Üstün F; Taştekin E; Taş A; Altun GD
    Curr Med Imaging Rev; 2019; 15(3):326-333. PubMed ID: 31989884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
    Hadiprodjo D; Ryan T; Truong MT; Mercier G; Subramaniam RM
    AJR Am J Roentgenol; 2012 Feb; 198(2):W185-90. PubMed ID: 22268210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?
    Kendi AT; Magliocca KR; Corey A; Galt JR; Switchenko J; Wadsworth JT; El-Deiry MW; Schuster DM; Saba NF; Hudgins PA
    AJR Am J Roentgenol; 2016 Sep; 207(3):635-40. PubMed ID: 27276388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parotid incidentalomas: a systematic review.
    Thompson C; Nolli T; Bannister M
    J Laryngol Otol; 2021 Sep; 135(9):765-769. PubMed ID: 34308809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18 fluorodeoxyglucose avid thyroid incidentalomas on PET/CT scan in cancer patients: how sinister are they?
    Hassan A; Riaz S; Zafar W
    Nucl Med Commun; 2016 Oct; 37(10):1069-73. PubMed ID: 27571130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study.
    Shmidt E; Nehra V; Lowe V; Oxentenko AS
    BMC Gastroenterol; 2016 Oct; 16(1):125. PubMed ID: 27716085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of metabolic heterogeneity as a reliable parameter for differentiating malignant parotid gland tumors.
    Kim BS; Kim SJ; Pak K
    Ann Nucl Med; 2016 Jun; 30(5):346-54. PubMed ID: 26897010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of conventional whole-body ¹⁸F-FDG PET/CT in the incidental findings of parotid masses.
    Wang HC; Zuo CT; Hua FC; Huang ZM; Tan HB; Zhao J; Guan YH
    Ann Nucl Med; 2010 Oct; 24(8):571-7. PubMed ID: 20640540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidental diagnosis of tumor thrombosis on FDG PET/CT imaging.
    Erhamamci S; Reyhan M; Nursal GN; Torun N; Yapar AF
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):287-94. PubMed ID: 26025479
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Baha A; Yildirim F; Kokturk N; Akdemir UO; Demircan S; Turktas H
    Clin Respir J; 2016 Nov; 10(6):740-745. PubMed ID: 25689088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
    Basu S; Mahne A; Iruvuri S; Alavi A
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.